Clinical Trial Update: A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study evaluating combinations of D-CIK immunotherapy with anti-PD-1 therapy in refractory solid tumors, including hepatocellular carcinoma, re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Colorectal Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Anti-PD-1
• D-CIK Immunotherapy (D-CIK immunotherapy (dendritic cell and cytokine-induced killer cells))

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN